Induction of Proteinuric Chronic Glomerular Disease in the Rat (Rattus norvegicus) by Intracardiac Injection of Doxorubicin Hydrochloride

Contemporary Topics in Laboratory Animal Science

Volumn 40, Issue 5, 2001, Pages 44-49

  Rangan, Gopala K ^b,c   Wang, Yiping ^a   Harris, David C H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; ELECTRON MICROSCOPY; GLOMERULUS; HEART; KIDNEY; MALE; NEPHROTIC SYNDROME; PATHOLOGY; PROTEINURIA; RAT; TAIL; VASCULARIZATION; WISTAR RAT;

ANIMALS; DOXORUBICIN; HEART; KIDNEY; KIDNEY GLOMERULUS; MALE; MICROSCOPY, ELECTRON; NEPHROTIC SYNDROME; PROTEINURIA; RATS; RATS, WISTAR; TAIL;

EID: 0035461812     PISSN: 10600558     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Blum, R. H., and S. K. Carter. 1974. Adriamycin: a new anticancer drug with significant clinical activity. Ann. Intern. Med. 80:249-259.
2. Abbate, M., D. Macconi, and G. Remuzzi. 1993. Mechanisms of glomerular injury, p. 153-200. In J. B. Hook and R. S. Goldstein (ed). Toxicology of the kidney. Raven Press, New York.
3. Grond, J., J. J. Weening, H. van Goor, et al. 1988. Application of puromycin aminonucleoside and Adriamycin to induce chronic renal failure in the rat. Contrib. Nephrol. 60:83-93.
4. Bertani, T., A. Poggi, and R. Pozzoni. 1982. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab. Invest. 46:16-23.
5. Gomez-Chiarri, M., A. Ortiz, J. L. Lerma, et al. 1994. Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats. Lab. Invest. 70:449-459.
6. Kaplan, B. S., L. Renaud, and K. N. Drummond. 1976. Effects of aminonucleoside, daunomycin, and Adriamycin on carbon oxidation by glomeruli. Lab. Invest. 34:174-178.
7. Zager, R. A., L. A. Baltes, H. M. Sharma, et al. 1984. Glomerulopathy does not increase renal susceptibility to acute ischemic injury. Am. J. Physiol. 246:F272-281.
8. Yokota, N., Y. Yamamoto, F. Iemura, et al. 1993. Increased plasma levels and effects of brain natriuretic peptide in experimental nephrosis. Nephron 65:454-459.
9. Wapstra F. H., G. Navis, P. E. de Jong, et al. 2000. Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established Adriamycin nephrosis. J. Am. Soc. Nephrol. 11:490-496.
10. Bertani, T., F. Cutillo, C. Zoja, et al. 1986. Tubulo-interstitial lesions mediate renal damage in Adriamycin glomerulopathy. Kidney Int. 30:488-496.
11. Kirby, G. M., and P. H. Bach. 1995. Enhanced hexachloro-1:3-butadiene nephotoxicity in rats with preexisting Adriamycin-induced nephrotic syndrome. Toxicol. Pathol. 23:303-312.
12. Hubmann, F. H. 1980. Intracardiac urography and retrograde pyelography of the rat. Lab. Anim. Sci. 30:60-63.
13. Tse, F. L., T. Chang, B. Finkelstein, et al. 1984. Influence of mode of intravenous administration and blood sample collection on rat pharmacokinetic data. J. Pharm. Sci. 73:1599-1602.
14. Huard, J., H. Lochmuller, G. Acsadi, et al. 1995. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2:107-115.
15. Katovich, M. J., C. H. Gelband, P. Reaves, et al. 1999. Reversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR. Am. J. Physiol. 277:H1260-1264.
16. Workcover Authority of New South Wales. 1995. Guidelines for handling cytotoxic drugs and related waste in health care establishments, 2nd edition. New South Wales Government Printers, Sydney, NSW, Australia.
17. Liss, R. H., D. W. Yesair, J. P. Schepis, et al. 1977. Distribution of Adriamycin and daunomycin in rats. Acta Pharmacol. Toxicol. 41(Suppl 1):128-129.
18. Rangan, G. K., Y. Wang, Y. C. Tay, et al. 1999. Inhibition of NF-κB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int. 56:118-134.
19. Baroni, E. A., R. S. Costa, C. G. da Silva, et al. 2000. Heparin treatment reduces glomerular injury but does not modify tubulointerstitial damage or the renal production of TGF-β. Nephron 84:248-257.
20. Stuhlman, R. A., J. T. Packer, and S. D. Rose. 1972. Repeated blood sampling of Mystromys albicaudatus. Lab. Anim. Sci. 22:268-270.
21. Deschenes, G., and A. Doucet. 2000. Collecting duct Na+/K+-AT-Pase activity is correlated with urinary sodium excretion in rat nephrotic syndromes. J. Am. Soc. Nephrol. 11:604-615.
22. Anderson, S., J. E. Tank, and B. M. Brenner. 2000. Renal and systemic manifestations of glomerular disease, p. 1871-1942. In B. M. Brenner (ed.), The kidney. W. B. Saunders Co., Philadelphia.
23. Guezmes, A., F. Fernandez, F. Garijo, et al. 1992. Correlation between tubulointerstitial nephropathy and glomerular lesions induced by adriamycin. Nephron 62:198-202.
24. Remuzzi, G., P. Ruggenenti, and A. Benigni. 1997. Understanding the nature of renal disease progression. Kidney Int. 51:2-15.
25. van Hoesel, Q. G., P. A. Steerenberg, J. A. Dormans, et al. 1986. Time-course study on doxorubicin-induced nephropathy and cardiomyopathy in male and female LOU/M/Wsl rats: lack of evidence for a causal relationship. J. Natl. Cancer Inst. 76:299-307.
26. Olson, H. M., and C. C. Capen. 1977. Subacute cardiotoxicity of Adriamycin in the rat: biochemical and ultrastructural investigations. Lab. Invest. 37:386-394.
27. Schwarz, E. R., C. Pollick, J. Dow, et al. 1998. A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc. Res. 39:216-223.
28. Solicia, E., L. Ballerini, O. Bellini, et al. 1981. Cardiomyopathy of doxorubicin in experimental animals. Factors affecting the severity, distribution and evolution of myocardial lesions. Tumori 67:461-472.
29. Brodsky, S., K. Gurbanov, Z. Abassi, et al. 1998. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Hypertension 32:746-752.